WWD : Ba&sh Names Jimmy Lam CEO for Asia-Pacific Amid Leadership Revamp

Ba&sh Names Jimmy Lam CEO for Asia-Pacific Amid Leadership Revamp
The appointment comes after the cofounders regained control of the brand and launched a structural revamp.

PARIS — French contemporary fashion label Ba&sh has appointed Jimmy Lam chief executive officer for the Asia-Pacific region, as the brand accelerates its post-restructuring turnaround and seeks to deepen its footprint across Asia.

Lam will lead the brand’s strategy and operations across key Asia-Pacific markets. He will report directly to Ba&sh co-CEO Dan Arrouas and will be based in Shanghai.

The move marks a strategic push by Ba&sh to make Asia a core growth territory, following a year of recovery driven by the European and Asian markets.

“Ba&sh is a brand with a distinctive spirit and global ambition, and I am excited to lead its journey across Asia-Pacific — a region rich in diversity, modern femininity, and opportunity,” Lam told WWD. “With a strong foundation and a passionate team, I look forward to accelerating our growth, deepening our connection with customers and building a dynamic presence that reflects the brand’s unique values. I am fully committed to contributing to Ba&sh’s continued success and shaping a bold future in this vibrant region.”

Lam was most recently CEO of SMCP Asia, parent company of French brands Sandro, Maje and Claudie Pierlot, where he spent nine years leading the group’s expansion and omnichannel development in the region. His career also includes senior roles at S.T. Dupont, Dolce & Gabbana, Chanel, Harvey Nichols and LVMH Moët Hennessy Louis Vuitton across Asia.

“His deep knowledge of Asian markets, combined with his proven expertise in building global brands and his strong ability to bring together multicultural teams, will be instrumental in supporting our growth ambitions,” said Arrouas, who leads Ba&sh alongside cofounders Sharon Krief and Barbara Boccara.

“Having progressively advanced from operational roles to senior leadership positions, Jimmy has developed a unique understanding of the retail industry, which will be a major asset for Ba&sh,” Arrouas added.

Founded in 2003, Ba&sh entered court-led restructuring in 2024, during which the three original founders regained control of the company. Under their “New Beginnings” turnaround plan, the brand is aiming to return to profitable growth and operational discipline with a renewed focus on full-price sales and key regional leadership hires.

In April, Ba&sh appointed former Iro CEO Rahav Zuta to lead its North American operations. Lam’s appointment is a complementary move to reinforce regional leadership to fuel global growth.

The privately held Ba&sh reported 300 million euros in revenue in 2024, with 25 percent of sales from online. The brand currently operates 320 stores globally and employs around 1,400 people.

Lam’s appointment is expected to help localize and scale the brand’s strategy in fast-evolving markets such as China and across Southeast Asia.

>>> US Research Calls I

Research Calls I
  • Upgrades
    • Alkermes (ALKS) upgraded to Outperform from Sector Perform at RBC Capital, tgt $44
    • Ciena (CIEN) upgraded to Buy from Neutral at Rosenblatt, tgt $175
    • H.B. Fuller (FUL) upgraded to Buy from Neutral at Seaport Research Partners, tgt $80
    • InterContinental Hotels Group (IHG) upgraded to Overweight from Underweight at JPMorgan
    • Ionis Pharmaceuticals (IONS) upgraded to Neutral from Sell at Goldman, tgt $65
    • Kenvue (KVUE) upgraded to Buy from Neutral at Rothschild & Co Redburn, tgt $22
    • Macerich (MAC) upgraded to Buy from Neutral at BofA Securities, tgt $23
    • One Gas (OGS) upgraded to Outperform from Neutral at Mizuho, tgt $86
    • Rapt Therapeutics (RAPT) upgraded to Outperform from Market Perform at Leerink, tgt $37
    • Riot Platforms (RIOT) upgraded to Overweight from Neutral at JPMorgan, tgt $19
  • Downgrades
    • Apellis Pharmaceuticals (APLS) downgraded to Sell from Neutral at Goldman, tgt $18
    • Braskem (BAK) downgraded to Neutral from Buy at UBS, tgt $3.80
    • CarMax (KMX) downgraded to In Line from Outperform at Evercore ISI, tgt $52
    • CarMax (KMX) downgraded to Perform from Outperform at Oppenheimer
    • Civitas Resources (CIVI) downgraded to Equal Weight from Overweight at Morgan Stanley, tgt $40
    • CleanSpark (CLSK) downgraded to Neutral from Overweight at JPMorgan, tgt $14
    • EOG Resources (EOG) downgraded to Sector Perform from Outperform at Scotiabank, tgt $130
    • First Merchants (FRME) downgraded to Market Perform from Outperform at Raymond James
    • IREN (IREN) downgraded to Underweight from Neutral at JPMorgan, tgt $24
    • Warner Bros. Discovery (WBD) downgraded to Sector Weight from Overweight at KeyBanc
  • Others
    • CRH (CRH) reinstated with a Buy at BofA Securities, tgt $128
    • First Horizon (FHN) initiated with a Neutral at DA Davidson, tgt $24
    • Kyndryl Holdings (KD) initiated with an Equal Weight at Morgan Stanley, tgt $30
    • Materion (MTRN) initiated with a Buy at Freedom Broker, tgt $136
    • Methanex (MEOH) initiated with an Outperform at National Bank, tgt $47
    • Mirion (MIR) initiated with an Overweight at JPMorgan, tgt $28
    • Paycom (PAYC) initiated with a Buy at Guggenheim, tgt $270
    • Paylocity (PCTY) initiated with a Neutral at Guggenheim
    • Rollins (ROL) initiated with an Overweight at JPMorgan, tgt $70
    • Spyre Therapeutics (SYRE) initiated with a Buy at Deutsche Bank, tgt $43
    • United Therapeutics (UTHR) initiated with an Outperform at RBC Capital, tgt $569
    • Valmont (VMI) initiated with an Overweight at JPMorgan, tgt $480

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • CNXC -20.5% (also increases dividend), LGCY -13.3%, COST -0.7%
Other news:
  • MESO -7.7% (informs that cell therapy products are designated US origin and not subject to tariffs)
  • FOSL -6.2% (announces effectiveness of registration statements)
  • NVX -4.7% (announced the sale of its subsidiary MD South Tenements, holder of contractual interests in the Mt Dromedary Natural Graphite Project in Queensland, in consideration of AUD $2 million cash)
  • ORGO -4.1% (provides update on Second Phase 3 ReNu study)
  • HFFG -3.8% (established $100 mln At-The-Marke equity offering program)
  • NN -3.7% (stock offering by selling shareholders)
  • QURE -2% (prices $300 mln offering consisting of common stock and warrants)
  • LTC -0.9% (acquires senior housing portfolio)
  • CIFR -0.9% (prices offering of $1.1 bln of 0.00% convertible senior notes due 2031)
  • NTST -0.9% (announces $450.0 million in additional financing commitments and amendments to existing credit facilities)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • LPTH +8.6%, BGC +1.6%
Other news:
  • CRNX +12.8% (FDA approves PALSONIFY for acromegaly)
  • NAK +6.1% (announced receipt of a $12 million mln representing the fourth tranche of investment; continues discussions with the government)
  • TXT +4.4% (awarded a $163 mln Army contract; also awarded a $359 mln modification to DLA contract)
  • MIR +3.6% (prices offering of 17,309,846 shares of common stock at $21.35 per share; offering of $325.0 mln of 0.00% Convertible Senior Notes due 2031)
  • LI +3.5% (launches Li i6)
  • ARCT +2.8% (launched a new presentation of KOSTAIVE, a self-amplifying mRNA vaccine against COVID-19)
  • HSHP +2.7% (to convert index-linked time charter for the Mount Etna to fixed rate time charter at $38,800 per day, gross, from October 1, 2025 to December 31, 2025) FUN +2.6% (Land & Buildings issues letter detailing why now is the time to finally unlock Six Flags' substantial trapped real estate value)
  • NFGC +2.3% (confirms at-surface high-grade core)
  • BBAR +2.2% (provides litigation update)
  • FTI +1.9% (awarded a substantial contract by ExxonMobil Guyana)
  • LLY +1.2% (announces Kisunla receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease)
  • GFI +1% (announces that Gold Road Resources Limited has received the requisite majority of votes from its shareholders in favor of the proposed acquisition)
  • HSBC +0.9% (confirms that Brendan Nelson will assume the role of Interim Group Chair with effect from 1 October 2025)
  • REGN +0.8% (Evkeeza ANGPTL3 antibody approved in the U.S. for children as young as 1 year old with ultra-rare form of high cholesterol)
  • BA +0.7% (awarded a $671 mln Defense Logistics Agency contract; Turkish Airlines orders up to 75 Boeing 787 Dreamliners, commits to more 737 MAX Jets; receives new 737 MAX order from Norwegian Group)

>>> Europe : Brokers Upgrades & Downgrades - 26th of September 2025 V3(++)

>>> Up
* Allegro Raised to Neutral at Goldman; PT 40 zloty
* Apple PT Raised to $290 from $260 at Evercore ISI (++)
* Ayvens Raised to Outperform at BNPP Exane; PT 12 euros
* Baidu ADRs PT Raised to $150 from $90 at Bernstein (++)
* Croda Raised to Overweight at Barclays; PT 3,100 pence
* Glenveagh Raised to Buy at Deutsche Bank; PT 2.15 euros
* InterContinental Hotels Raised to Overweight at JPMorgan
* Kenvue Raised to Buy at Rothschild & Co Redburn; PT $22 (+)
* Lindt & Spruengli Raised to Market Perform at Bernstein (++)
* Knorr-Bremse Raised to Buy at M.M. Warburg; PT 92 euros (+)
* Microsoft PT Raised to $625 from $582 at Morgan Stanley
* SwedenCare Raised to Buy at Pareto Securities; PT 40 kronor
* Tesla PT Raised to $435 from $345 at Deutsche Bank (++)
* Yellow Cake PT Raised to 830 pence from 690 pence at BofA (++)

>>> Down
* Accenture PT Cut to $280 from $300 at Evercore ISI
* Aena Cut to Underweight at JPMorgan; PT 21 euros
* Airbus Cut to Sell at mwb research AG; PT 170 euros (++)
* Brunello Cucinelli Cut to Neutral at Oddo BHF; PT 83 euros
* Colruyt Cut to Underweight at JPMorgan; PT 28.60 euros
* Guillemot Cut to Neutral at Invest Securities SA; PT 5.50 euros (+)
* Hanza Cut to Hold at Nordea
* Neste Cut to Underperform at BofA (++)
* Norbit Cut to Neutral at SpareBank; PT 200 kroner
* Pernod Ricard Cut to Neutral at BofA (++)

>>> Initiation
* Eni Reinstated Neutral at BofA (++)
* Repsol Reinstated Neutral at BofA (++)
* Rheinmetall Rated New Market Perform at Bernstein
* Sobi ADRs Rated New Underperform at BNPP Exane; PT $14.70
* Zurich Airport Reinstated Overweight at JPMorgan

>>> Call
* BofA Strategists See 10% Stoxx 600 Drop on Economic Slowdown (++)
* Colruyt Double-Downgraded at JPMorgan on Unsupportive Outlook
* IHG Gets Double-Upgrade as JPMorgan Flags Earnings Visibility
* Rheinmetall Priced For Perfection, Bernstein is Market Perform
* Zurich Airport New Overweight at JPMorgan, Aena Downgraded

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • TXT +4.4%, NAK +3.8%, MIR +3.6%, CIFR +2.7%, HSHP +2.6%, LI +2.4%, NFGC +2.3%, BBAR +2.2%, LLY +1.8%, BGC +1.6%, E +1.5%, HROW +1%, PSEC +0.9%, ARCT +0.9%, EXK +0.7%, BA +0.6%
  • Gapping down:
    • CNXC -19.4%, LGCY -15.1%, ORGO -12%, FOSL -6.2%, LPTH -5.4%, HFFG -3.8%, NN -3.7%, LTC -1.8%, SBET -1.5%, QURE -1.1%, SAP -0.8%, MESO -0.8%, INGN -0.7%

FT : Ørsted in talks to sell stake in £8.5bn UK wind project to Apollo

Ørsted in talks to sell stake in £8.5bn UK wind project to Apollo
Danish developer and US private capital group discuss deal for Hornsea 3 wind farm

The world’s largest offshore wind developer, Ørsted, is in talks to sell a stake in its flagship UK project to Apollo as it tries to shore up its balance sheet following a run of setbacks.

Ørsted and the US private capital group are discussing a deal for a 50 per cent share of the £8.5bn Hornsea 3 wind farm off the east coast of the UK, according to people familiar with the matter.

The 2.9-gigawatt project is one of eight offshore wind farms Ørsted is trying to finish building around the world amid higher costs, supply-chain strains and political disruption that have stretched its finances.

The Danish company has said it wants to raise at least DKr35bn ($5.5bn) combined from the sales of Hornsea 3, a stake in an offshore wind project in Taiwan and its European onshore wind business.

The Copenhagen-listed group is also raising in the region of DKr60bn from shareholders in a rights issue, having failed to sell a stake in its Sunrise Wind project off the US east coast.

Investors have been spooked by Donald Trump’s hostility to the sector, spurred by the US president’s long-standing animosity towards wind turbines, although political sentiment in Europe is more favourable.

Ørsted launched the Hornsea 3 sale process late last year and said in August that it had a preferred bidder for the stake, without revealing who this was. People familiar with the matter now say the negotiations are with Apollo, the New York-based firm that manages more than $800bn.

Apollo has been an active dealmaker in European energy infrastructure, including a move this month with RWE to invest in Germany’s electricity grid and $4.5bn in financing announced in June for the UK’s Hinkley Point nuclear energy plant.

Ørsted traditionally sells stakes in offshore wind projects to raise funds for the next ones, although this model has become more challenging due to the Trump administration’s hostility to the sector as well as higher interest rates.

It sold stakes in four UK offshore wind farms to the Canadian infrastructure investor Brookfield for about £1.7bn last year.

A sale of Hornsea 3 would be a further boost for Ørsted in a week when it persuaded a US judge to lift a Trump administration order to stop work on its Revolution Wind project off the coast of Rhode Island.

Yet Ørsted’s problems are not all connected to the president, and the company was suffering even before he returned to power, with rising costs and supply-chain strains buffeting the entire industry.

Ørsted had to walk away from two projects in the US in 2023 and has halted development of another UK scheme, Hornsea 4, blaming higher costs and the risks of construction delays.

Ørsted and Apollo declined to comment.

FT : Eni among six oil companies fined €936mn over fuel price collusion

Eni among six oil companies fined €936mn over fuel price collusion
Italy’s competition watchdog imposes one of the biggest penalties imposed by a national regulator in Europe

Italy’s competition watchdog has fined Eni and other five oil companies more than €900mn for allegedly setting up a fuel price cartel in one of the biggest penalties imposed by a national regulator in Europe.

The AGCM said on Friday it found that the most “important oil companies operating in Italy engaged in an agreement restricting competition in the sale of automotive fuel” and imposed fines worth a combined €936mn. 

Eni was handed the largest penalty of €336mn, while ExxonMobil-owned Esso, Italy’s IP and Kuwaiti Q8 were fined between €129mn and €172mn, the regulator’s statement said. Saras and Tamoil, owned by Italy’s billionaire Moratti family and Netherlands based Oilinvest respectively, both had penalties below €100mn.

The regulator said the action had followed a “complex investigation” triggered by a whistleblower complaint. The petrol companies “colluded to determine the value of the bio-based component added to the price of fuel”, according to the statement. 

The specific component was introduced by oil majors to comply with regulatory requirements. The competition authority said the cartel began in 2020 and lasted for three years, during which time the price of the bio-based component increased from about €20 a cubic metre to about €60.

The companies were not immediately available for comment.

>>> Europe : Brokers Upgrades & Downgrades - 26th of September 2025 V2(+)

>>> Up
* Allegro Raised to Neutral at Goldman; PT 40 zloty
* Ayvens Raised to Outperform at BNPP Exane; PT 12 euros
* Croda Raised to Overweight at Barclays; PT 3,100 pence
* Glenveagh Raised to Buy at Deutsche Bank; PT 2.15 euros
* InterContinental Hotels Raised to Overweight at JPMorgan
* Kenvue Raised to Buy at Rothschild & Co Redburn; PT $22 (+)
* Knorr-Bremse Raised to Buy at M.M. Warburg; PT 92 euros (+)
* Microsoft PT Raised to $625 from $582 at Morgan Stanley
* SwedenCare Raised to Buy at Pareto Securities; PT 40 kronor

>>> Down
* Accenture PT Cut to $280 from $300 at Evercore ISI
* Aena Cut to Underweight at JPMorgan; PT 21 euros
* Brunello Cucinelli Cut to Neutral at Oddo BHF; PT 83 euros
* Colruyt Cut to Underweight at JPMorgan; PT 28.60 euros
* Guillemot Cut to Neutral at Invest Securities SA; PT 5.50 euros (+)
* Hanza Cut to Hold at Nordea
* Norbit Cut to Neutral at SpareBank; PT 200 kroner

>>> Initiation
* Rheinmetall Rated New Market Perform at Bernstein
* Sobi ADRs Rated New Underperform at BNPP Exane; PT $14.70
* Zurich Airport Reinstated Overweight at JPMorgan

>>> Call
* Colruyt Double-Downgraded at JPMorgan on Unsupportive Outlook
* IHG Gets Double-Upgrade as JPMorgan Flags Earnings Visibility
* Rheinmetall Priced For Perfection, Bernstein is Market Perform
* Zurich Airport New Overweight at JPMorgan, Aena Downgraded